EPM2A anticorps (Internal Region, Isoform A)

N° du produit ABIN375087

Détail du produit anti-EPM2A anticorps

Antigène: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Épitope: Internal Region, Isoform A

Reactivité: Humain, Rat, Souris, Boeuf (Vache), Chien

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp EPM2A est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Séquence: C-EATGHTNEMK HTTD

Specificité: This antibody is expected to recognize isoform a only.

Réactivité croisée (Details): Species reactivity (expected):Mouse, Rat, Canine, Bovine.
Species reactivity (tested):Human.

Purification: Affinity Chromatography

Immunogène: Peptide with sequence from the internal region of the protein sequence according to NP_005661.1. Genename: EPM2A

Information d'application

Indications d'application: Peptide ELISA: 1/16000. Western Blot: 0.1 - 0.3 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Tris buffered saline, pH ~7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur EPM2A

Antigène: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Autre désignation: Laforin (EPM2A Produits)

Synonymes: anticorps TG-B, anticorps Tg(TcraK,TcrbK)TG-BFlv, anticorps EPM2, anticorps MELF, anticorps laforin, anticorps EPM2A, laforin glucan phosphatase, anticorps epilepsy, progressive myoclonic epilepsy, type 2 gene alpha, anticorps EPM2A, anticorps Epm2a

Sujet: EPM2A is a dual specificity protein phosphatase. It may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules (polyglucosans). Defects in EPM2A are a cause of Lafora disease (LD), also known as myoclonic epilepsy of Lafora (MELF) or epilepsy progressive myoclonic 2 (EPM2). LD is the most common and severe form of adolescent-onset progressive epilepsy.Synonyms: EC=3.1.3.16, EC=3.1.3.48, EPM2A, LAFPTPase, Lafora PTPase, Laforin

ID gène: 7957

NCBI Accession: NP_001018051

UniProt: O95278

Pathways: Cellular Glucan Metabolic Process